Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Aminolevulinic Acid Hydrochloride in Glioblastoma Multiforme: NCT06665724 Clinical Landscape Report 2026
15 October 2026
NCT06665724 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ABBV-291 in High grade B-cell lymphoma: NCT06667687 Clinical Landscape Report 2026
15 October 2026
NCT06667687 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Propranolol Hydrochloride in Soft Tissue Sarcoma: NCT06670976 Clinical Landscape Report 2026
15 October 2026
NCT06670976 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dinutuximab beta in Osteosarcoma: NCT06669013 Clinical Landscape Report 2026
15 October 2026
NCT06669013 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Glofitamab in Large B-cell lymphoma: NCT06670105 Clinical Landscape Report 2026
15 October 2026
NCT06670105 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cadonilimab in Kidney Neoplasms: NCT06670300 Clinical Landscape Report 2026
15 October 2026
NCT06670300 clinical landscape for Kidney Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06669143 Clinical Landscape Report 2026
15 October 2026
NCT06669143 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in Recurrent Glioblastoma: NCT06672575 Clinical Landscape Report 2026
15 October 2026
NCT06672575 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nuvastatic in Breast Cancer: CTRI/2024/11/076299 Clinical Landscape Report 2026
15 October 2026
CTRI/2024/11/076299 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Hemangiosarcoma: NCT06673628 Clinical Landscape Report 2026
15 October 2026
NCT06673628 clinical landscape for Hemangiosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Breast Cancer: ACTRN12624001340527 Clinical Landscape Report 2026
15 October 2026
ACTRN12624001340527 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Arsenious Acid in Triple Negative Breast Cancer: NCT06678048 Clinical Landscape Report 2026
15 October 2026
NCT06678048 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.